Research
Hormonal
Obesity increases the risk of kidney stones (nephrolithiasis) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, and sodium excretion, as well as insulin resistance.
Obesity increases your risk of kidney stones by changing your urine chemistry. To protect your kidneys, stay hydrated, limit excessive protein and sodium intake, and manage your weight through balanced nutrition.
GoodSupportsHIGH confidence
Obesity is associated with a number of risk factors contributing to the higher incidence and prevalence of nephrolithiasis. Higher body weight is associated with lower urine pH [48] and increased urinary oxalate [49], uric acid, sodium and phosphate excretion [50]... The insulin resistance characteristic of obesity may also predispose to nephrolithiasis [51]...
Why this rating
Supported by multiple population-based studies and mechanistic explanations.
Source
Obesity and kidney disease: hidden consequences of the epidemic
Csaba P. Kövesdy et al. · Journal of Nephrology · 2017
DOI 10.1007/s40620-017-0377-y
narrative_reviewCited 79×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High body mass index (BMI) is a strong independent risk factor for the development and progression of Chronic Kidney Disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.Good
- Lifestyle interventions involving caloric restriction and increased physical activity reduce the risk of incident Chronic Kidney Disease in overweight or obese diabetic patients by approximately 30%.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →